ZOLL Medical Corporation (NASDAQ: ZOLL) has received 510(k) clearance from the U.S. Food and Drug Administration for a new model of the ZOLL E Series Monitor/ Defibrillator with carbon monoxide (CO) measurement. The product is available for shipment immediately. CO measurement is a breakthrough which helps rescuers noninvasively and immediately diagnose and treat patients poisoned by CO. Undetected, untreated episodes can lead to permanent neurological and cardiac damage, often resulting in death.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
About ZOLL Medical Corporation
ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
